Results from the SOUL Trial: The Diabetologists' Perspective
Diabetes Insights - Breakthroughs and InnovatorsShow Notes
At the EASD 2024 Annual Meeting, the SOUL trial attracted significant attention as the first study to show cardiovascular risk reduction using an oral GLP-1 receptor agonist. In this episode, Dr Rodica Busui (Oregon Health & Science University-OHSU, Oregon, USA) explains the trial’s major outcomes, including a 14% reduction in major adverse cardiovascular events -matching results previously observed with injectable GLP-1 formulations.
The discussion highlights the potential impact of an oral agent on clinical practice, including improved accessibility, suitability for older adults, and earlier use in the treatment pathway. Dr Busui also reviews new data on heart failure phenotypes, particularly HFpEF, and the growing need to address cardiometabolic multimorbidity in people with type 2 diabetes.
Another key topic is the high proportion of participants using SGLT2 inhibitors in the trial. The reassuring safety data regarding combined therapy offers important guidance for clinicians prescribing contemporary cardiometabolic treatments.
This episode provides a clear and timely overview of how oral GLP-1 therapies may influence the future of cardiovascular and diabetes care.
More from Diabetes Insights - Breakthroughs and Innovators
In this EASD TV interview, Prof. Zachary Gerhart-Hines (Novo Nordisk Foundation Center for Basic Metabolic Research), 61st EASD Minkowski Prize recipient, discusses research into the neurokinin-2 receptor (NK2R) and its potential to change how we approach weight management and metabolic health. Where many existing treatments focus on reducing food intake, NK2R activation could offer a complementary strategy by increasing energy expenditure, influencing appetite and improving insulin sensitivity.
How does exercise stimulate glucose uptake in muscle and what can this teach us about treating type 2 diabetes?
Prof. Anette-Gabriele Ziegler, this year’s Claude Bernard Prize Lecture recipient, reflects on her career in type 1 diabetes research and the evolution of our understanding of the disease.
The EASD’s first clinical practice guideline on the assessment and management of diabetes distress in adults living with type 1 or type 2 diabetes has now been published in Diabetologia.
How can people living with diabetes help shape the future of diabetes care?